Navigation Links
Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
Date:5/6/2010

RESEARCH TRIANGLE PARK, N.C., May 6 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Thomas A. Pitler, Ph.D., has joined the company as Vice President, Business Development.

Dr. Pitler brings to Chimerix more than 25 years of experience, combining skills in business development and strategic planning with a strong scientific and financial background.  Dr. Pitler has overall responsibility for the business development activities at Chimerix, advancing and leveraging the company's deep pipeline of proprietary oral antiviral therapeutics in its transition to a development-stage company.  In this newly-created position, Dr. Pitler reports directly to Kenneth I. Moch, President and Chief Executive Officer.

"Tom brings to Chimerix the notable combination of industry deal-making with operations and research experience," said Mr. Moch.  "Tom is uniquely qualified to expand Chimerix's strategic alliances and opportunities to develop significant value from Chimerix's extraordinary pipeline of therapeutics against a range of challenging viral diseases.  We look forward to working with him."

Prior to joining Chimerix, Dr. Pitler was Senior Vice President, Chief Business and Financial Officer at Neurogen, Inc., which was recently acquired by Ligand Pharmaceuticals.   He joined Neurogen in 1995 as a scientist in research and development.  In 1999, he became head of business development, subsequently moving into business and corporate development positions of increasing responsibility.  While at Neurogen, Dr. Pitler was responsible for the in-licensing of a Phase II clinical-stage compound from Wyeth, and led multi-million dollar out-licensing and technology deals with several international pharmaceutical companies.  Before joining Neurogen, Dr. Pitler was a Research Assistant Professor at the University of Maryland School of Medicine and held other academic positions.  He received a B.A. in Biology and a Ph.D. in Physiology from Wake Forest University.   

About Chimerix

Chimerix is developing antiviral therapeutics to treat life-threatening diseases.  Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza.  The company's lead compound, CMX001, is in Phase 1 and Phase 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients.  CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release.  CMX157, a late-stage preclinical candidate, is a new chemical entity created by applying Chimerix's PIM (Phospholipid Intramembrane Microfluidization) Conjugate Technology to chemically modify tenofovir, an approved HIV drug.  CMX157 is being developed as a potential once-weekly nucleoside analogue against HIV infections.  Building on the company's extensive chemical library, Chimerix is also pursuing translational medicine efforts to address malaria, dengue fever and other public health needs.  Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases.  Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix.com.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Quark Pharmaceuticals Appoints New Chief Medical Officer
7. West Pharmaceutical Services, Inc. Appoints New Director
8. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
9. Curemark Appoints Preeminent Pediatrics Gastroenterologist
10. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
(Date:10/4/2017)... WESTWOOD, Mass. , Oct. 4, 2017  According to the Centers ... by the end of October . PhysicianOne Urgent Care is helping communities ... Westchester, NY , by offering no-cost* flu shots through ... , as mandated by certain health insurance regulations. ... The best time to get a flu shot is by ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Leading pediatric oncology ... in Washington, D.C., for the 49th Congress of the International Society of Paediatric ... President of the Center for Cancer and Blood Disorders at Children’s National, ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... ... Cal Dining at the University of California Berkeley, and other leading institutions in ... the buying power of institutions to change the way animals are raised for ...
Breaking Medicine News(10 mins):